Viking Phase II Update Shows Sustained Response After Treatment’s End

 
• By Joseph Haas
  
SC2008_Fatty Liver_274834199_1200.jpg
Viking thinks its THR beta agonist for NASH could be best in class
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D